Credential
PhD
Areas of Study & Research
Activation of the receptor for advanced glycation endproducts (RAGE) is believed to be critically involved in diabetic complications, neurodegerative disorders, and several cancers by supporting tissue inflammation. RAGE can be activated by several structurally unrelated ligands including S100 proteins, amyloid forming peptides, and advanced glycation endproducts. We are working on understanding the ligand binding properties of RAGE using biophysical and biochemical methods. We are also interested in discovering and developing small molecules and peptides that can modulate RAGE activation.
Previous Work
1998-1999 - Torrey Pines Institute of Molecular Studies, San Diego, SNF Postdoctoral Research Fellow, Combinatorial Chemistry
1999-2005 - The Scripps Research Institute, La Jolla, Research Associate, Molecular and Structural Biology
2005-2009 - Florida Atlantic University, Boca Raton, Assistant Professor, Biochemistry
Education
- 1998 - PhD Biochemistry, Swiss Federal Institute of Technology (Dr. sc. ETH), Switzerland PhD
- 1994 - MS Chemistry (Dipl-Chemiker), Technische Universität Braunschweig, Germany
Publications
Indurthi VS, Leclerc E, Vetter SW, Calorimetric investigation of diclofenac drug binding to a panel of moderately glycated serum albumins, Eur J Pharm Sci 59 (2014) 158-168
Otvos L Jr., Vetter SW, Koladia M, Knappe D, Schmidt R, Ostorhazi E, Kovalszky I, Bionda N, Cudic P, Surmacz E, Wade JD, Hoffmann R, The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor, Amino Acids 46 (2014) 873-882
Meghnani V, Wagh A, Indurthi VS, Koladia M, Vetter SW, Law B, Leclerc E, The Receptor for Advanced Glycation End Products influences the expression of its S100 protein ligands in melanoma tumors, Int J Biochem Cell Biol 57 (2014) 54-62
Meghnani V, Vetter SW, Leclerc E, RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line, Biochim Biophys Acta 1842 (2014) 1017-1027
Vetter SW, Phage Display Selection of Peptides that Target Calcium Binding Proteins, Methods Mol. Biol. 963 (2013) 215-235
Indurthi VS, Leclerc E, Vetter SW, Interaction Between Glycated Serum Albumin and AGE-Receptors Depends on Structural Changes and the Glycation Reagent, Arch. Biochem. Biophys. 528 (2012) 185-196
Vetter SW, Indurthi VS, Moderate glycation of serum albumin affects folding, stability, and ligand binding, Clin Chim Acta 412 (2011) 2105-2116
Leclerc E, Sturchler E, Vetter SW, The S100B/RAGE Axis in Alzheimer's Disease, Cardiovasc Psychiatry Neurol 2010 (2010) 539-581.
Vetter SW, Terentis A, Osborn RL, Dawson JH, Goodin DB; Replacement of the axial histidine heme ligand with cysteine in nitrophorin I: Spectroscopic and crystallographic characterization; J. Biol. Inorg. Chem. (2009), 14(2)(2009), 179-191
Leclerc E, Fritz G, Vetter SW, Heizmann CW; Binding of S100 proteins to RAGE: An update; Biochim. Biophys. Acta. (2009), 1793, 993-1007
Leclerc E, Sturchler E, Vetter SW, Heizmann CW; Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer’s disease. Reviews in the Neurosciences, (2009), 20, 95-110
Leclerc E, Heizmann CW, Vetter SW, RAGE and S100 Protein Transcription Levels are Highly Variable in Human Melanoma Tumors and Cells. General Physiol. Biophys. (2009), 28, F65-75